Acute leukemia is treated in phases, starting with intensive chemotherapy to push the disease into remission, followed by additional therapy to keep it there. The specific approach depends on whether you have acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), your age, and the genetic profile of the leukemia cells. Treatment typically lasts months for AML and up to three years for ALL, though newer targeted therapies are beginning to shorten and simplify some regimens.
The Two Main Types of Acute Leukemia
Acute leukemia comes in two forms, and the distinction matters because they’re treated differently. AML involves cancerous white blood cells from the myeloid line, which normally develops into infection-fighting cells. ALL involves cancerous cells from the lymphoid line, which normally becomes part of the immune system. AML is more common in older adults, while ALL is the most common childhood cancer and also affects adults.
Five-year survival varies significantly. For AML, the overall five-year survival rate is about 33%, according to the most recent SEER data (2015 to 2021). For adults over 65, that drops to around 20%. ALL generally has better outcomes, especially in children, where cure rates exceed 85%. Adult ALL outcomes are less favorable, partly because adults tolerate the intensive chemotherapy protocols less well, leading to more dose reductions and treatment interruptions.
Induction: The First Push Toward Remission
Treatment begins with induction therapy, the most intensive phase. The goal is complete remission, meaning leukemia cells are no longer detectable in the bone marrow using standard tests. For AML, the classic approach is called “7+3”: seven days of one chemotherapy drug given continuously through an IV, plus three days of a second drug. This requires a hospital stay, typically three to four weeks, because the treatment wipes out healthy blood cells along with cancerous ones. During this time, you’ll need blood transfusions and close monitoring for infections.
For ALL, induction also uses multiple chemotherapy drugs but follows a different schedule. Adult ALL regimens have traditionally stretched across two and a half to three years total, modeled on the highly successful childhood protocols. The induction phase itself lasts roughly four to six weeks.
Consolidation: Preventing Relapse
Reaching remission is not enough. Without further treatment, virtually all patients relapse. Consolidation therapy addresses the leukemia cells that survive induction but aren’t detectable by standard tests. For AML, the standard consolidation involves multiple cycles of high-dose chemotherapy. Research has shown that high-dose regimens are clearly superior to standard-dose options for both preventing relapse and improving overall survival. Guidelines typically recommend two to four consolidation cycles.
For ALL, consolidation is followed by a longer maintenance phase. Adults may receive cycles of combination chemotherapy, sometimes alternating with newer immunotherapy drugs, followed by 15 or more months of lower-intensity maintenance treatment. ALL treatment also includes injections of chemotherapy directly into the spinal fluid to prevent leukemia from spreading to the brain and spinal cord. Depending on the regimen, patients receive anywhere from 8 to 22 of these injections over the course of treatment.
How Genetic Testing Shapes Your Treatment
One of the biggest shifts in leukemia treatment over the past decade is the use of genetic testing to match patients with specific therapies. When you’re diagnosed, your leukemia cells are tested for mutations and chromosomal changes that predict how aggressive the disease is and which drugs are most likely to work.
Several FDA-approved targeted drugs now exist for specific mutations. For AML patients whose leukemia carries mutations in genes called IDH1 or IDH2, three approved drugs can block the abnormal proteins those mutations produce. One of these can be used as frontline therapy combined with a less intensive chemotherapy, making it an option for older patients who can’t tolerate standard high-dose treatment. For AML with a different mutation called FLT3, a targeted drug can be added to standard chemotherapy during both induction and consolidation.
These genetic results also determine whether you’ll be recommended for a stem cell transplant. Patients whose leukemia has favorable genetic markers and responds well to chemotherapy can often avoid transplant entirely. Those with intermediate or unfavorable genetics, or whose disease shows signs of lingering after treatment, are more likely to benefit from transplant.
When a Stem Cell Transplant Is Recommended
A stem cell transplant (using donor cells) replaces your bone marrow with healthy marrow from someone else. It’s the most intensive treatment option and carries significant risks, but for many patients it offers the best chance of long-term cure. The decision to transplant depends heavily on a test called minimal residual disease (MRD) testing, which can detect as few as one leukemia cell among ten thousand normal cells.
For AML, patients who still have detectable residual disease after induction or consolidation consistently benefit from transplant. In one analysis of patients with a common AML subtype, those with persistent residual disease who received a transplant had a three-year survival of 61%, compared to just 24% for those who didn’t. Patients who test negative for residual disease and have favorable genetics often do well without transplant.
For ALL, the picture is similar. Patients with residual disease levels at or above a certain threshold after initial treatment are considered transplant candidates. The 2024 European guidelines recommend transplant for ALL patients who still have detectable disease above one in ten thousand cells after three rounds of therapy.
MRD Testing Guides Treatment Intensity
MRD testing has become one of the most important tools in leukemia treatment. Rather than giving every patient the same intensity of therapy, doctors now use MRD results to calibrate. Patients with very low MRD levels after induction (below one in ten thousand) generally have a favorable outlook and can often continue with lower-intensity chemotherapy, reducing side effects while maintaining effectiveness. Patients with higher residual disease levels may need more aggressive strategies, including transplant.
This testing happens at multiple points during treatment, not just once. Continuous monitoring helps catch early signs of relapse and allows your medical team to adjust course before the disease becomes fully apparent again.
A Special Case: Acute Promyelocytic Leukemia
One subtype of AML, called acute promyelocytic leukemia (APL), deserves special mention because its treatment is dramatically different and remarkably successful. Instead of relying primarily on chemotherapy, APL is treated with two non-chemotherapy drugs: a vitamin A derivative and an arsenic-based compound. This combination works because APL cells have a specific genetic change that makes them uniquely vulnerable to these agents.
For patients with standard-risk APL, this near-chemotherapy-free combination is the FDA-approved standard. Results from the APOLLO trial recently showed it works for high-risk APL as well. In that trial, patients receiving the arsenic-based combination had a two-year event-free survival of 88%, compared to 71% for those on traditional chemotherapy. Only 1.5% of patients on the newer regimen experienced molecular relapse, versus 12.3% on standard chemotherapy. Serious side effects were also cut nearly in half. Patients on this regimen don’t need long-term maintenance therapy.
CAR T-Cell Therapy for ALL That Returns
For patients with ALL that comes back after treatment or doesn’t respond to standard therapy, a newer option called CAR T-cell therapy has shown striking results. This treatment involves removing some of your own immune cells, engineering them in a lab to recognize and attack leukemia cells, then infusing them back into your body.
Two CAR T-cell products are currently FDA-approved for ALL. One is approved for patients up to age 25, the other for adults. In clinical studies, about 80% of patients with relapsed or treatment-resistant ALL achieved complete remission after CAR T-cell therapy. One real-world study of 255 patients reported an initial remission rate of 85.5%. Newer versions targeting two markers on leukemia cells simultaneously have shown even higher initial response rates, around 90% in early trials.
CAR T-cell therapy can cause significant side effects, including a severe immune reaction as the engineered cells multiply and attack the leukemia. This requires close monitoring in a specialized center, typically with a hospital stay of one to two weeks after infusion.
Supportive Care During Treatment
Because leukemia treatment destroys healthy blood cells along with cancerous ones, supportive care is a major part of the process. You’ll likely need red blood cell transfusions when your levels drop below a certain threshold, typically when hemoglobin falls below 70 grams per liter for non-bleeding patients. Platelet transfusions help prevent dangerous bleeding when platelet counts drop.
Infection is the most serious day-to-day risk during treatment. When your white blood cell count bottoms out, a period called neutropenia, even minor infections can become life-threatening. Preventive antibiotics and antifungal medications are commonly used, though the approach tends to be broad rather than targeted at specific organisms. You may be advised to avoid certain foods or crowds, though highly restrictive “neutropenic diets” aren’t strongly supported by evidence and may actually worsen nutritional deficiencies at a time when good nutrition matters.
Fatigue, nausea, mouth sores, and hair loss are common during intensive treatment phases. Most of these side effects are temporary and improve once blood counts recover between cycles, though the cumulative toll of multiple rounds of treatment can be significant. Physical deconditioning from long hospital stays is real, and maintaining whatever activity level you can manage helps with recovery.